You can confirm or exclude ATTRv amyloidosis through genetic testing

Genetic testing is a crucial part of diagnostic procedures and recommendations. Testing the gene encoding
transthyretin (TTR) should be performed on patients with warning signs or a family history of ATTRv amyloidosis.^1, 6

A new diagnostic service has been launched

A free service easing the diagnosis of ATTRv amyloidosis is now available to you and your patients through a partnership between Alnylam and ARCHIMEDLife.

GeneAct™ is a trademark of Alnylam Pharmaceuticals

You are about to visit a website that is not under the control of Alnylam Pharmaceuticals. Therefore, Alnylam does not endorse its content and is not responsible for its accuracy or practices/standards it includes. Alnylam Pharmaceuticals is not responsible for the security level of third-party websites. All contained trademarks are the property of their respective owners.

If you have any questions, send them by email to info@archimedlife.com

Alnylam provides financial support for GeneAct™ testing, but the responsibility for the services remains with ARCHIMEDLife.

References:
1. Maurer MS, et al. for the Amyloidosis Research Consortium. Circ Heart Fail. 2019; 12(9): e006075.
2. Adams D, et al. Nat Rev Neurol. 2019; 15(7): 387–404.
3. Swiecicki PL, et al. Amyloid. 2015; 22(2): 123–131.
4. Sattianayagam PT, et al. Eur Heart J. 2012; 33(9): 1120–1127.
5. González-Duarte A, et al. J Neurol. 2020; 267(3): 703–712.
6. Adams D, et al. J Neurol. 2021; 268(6): 2109–2122.
7. Polydefkis M, et al. Presented at PNS Annual Meeting; 22–26 June 2019;  Genoa, Italy.
8. Kristen AV, et al. Neurodegener Dis Manag. 2019; 9(1): 5–23.